Adaptive Biotechnologies Corporation
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $277.0M | $179.0M | $170.3M | $185.3M | $154.3M | $98.4M | $85.1M | $55.7M |
| MRD | $212.3M | $145.5M | $102.7M | $87.1M | $66.2M | $32.6M | — | — |
| Immune Medicine | $64.6M | $33.4M | $67.5M | $98.2M | $88.1M | $65.7M | — | — |
| Cost of Revenue | $71.4M | $72.1M | $75.6M | $57.9M | $49.3M | $22.5M | $22.3M | $19.7M |
| Gross Profit | $205.6M | $106.9M | $94.7M | $127.4M | $105.0M | $75.9M | $62.8M | $36.0M |
| Gross Margin | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% | 73.8% | 64.7% |
| Operating Expenses | ||||||||
| Research & Development | $93.8M | $103.0M | $122.1M | $141.8M | $142.3M | $116.1M | $70.7M | $39.2M |
| SG&A Expense | $72.7M | $72.8M | $83.9M | $88.5M | $74.5M | $49.5M | $30.3M | $20.4M |
| Operating Income | $-57.1M | $-162.5M | $-227.0M | $-200.2M | $-209.0M | $-152.8M | $-78.4M | $-49.8M |
| Operating Margin | -20.6% | -90.8% | -133.3% | -108.0% | -135.4% | -155.3% | -92.1% | -89.4% |
| Interest Expense | $11.8M | $11.6M | $13.8M | $4.2M | — | — | — | — |
| Pretax Income | $-59.5M | $-159.6M | $-225.3M | $-200.4M | $-207.3M | $-146.2M | $-68.6M | — |
| Income Tax Expense | $0 | $0 | $0 | — | — | — | — | — |
| Net Income | $-59.5M | $-159.5M | $-225.3M | $-200.2M | $-207.3M | $-146.2M | $-68.6M | $-46.4M |
| Net Margin | -21.5% | -89.1% | -132.3% | -108.0% | -134.3% | -148.6% | -80.6% | -83.4% |
| EPS (Basic) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 | $-1.11 | $-1.01 | $-3.67 |
| EPS (Diluted) | $-0.39 | $-1.08 | $-1.56 | $-1.40 | $-1.48 | $-1.11 | $-1.01 | $-3.67 |
| Shares Outstanding (Basic) | 151.7M | 147.1M | 144.4M | 142.5M | 140.4M | 131.2M | 125.2M | 12.8M |
| Shares Outstanding (Diluted) | 151.7M | 147.1M | 144.4M | 142.5M | 140.4M | 131.2M | 125.2M | 12.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |